ARVN Q1 2025 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$189M+646.2% YoY

Gross Profit

$189M100.0% margin

Operating Income

$71M37.8% margin

Net Income

$83M43.9% margin

EPS (Diluted)

$1.14

QoQ Revenue Growth

+218.9%

Cash Flow

Operating Cash Flow

-$89M

Free Cash Flow

-$89M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$341M

Stockholders' Equity

$660M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$189M	$25M	+646.2%
Gross Profit	$189M	$24M	+700.0%
Operating Income	$71M	-$83M	+185.7%
Net Income	$83M	-$69M	+219.5%

Revenue Segments

License

$130M100%